MediGene concentrates on researching, developing, and commercializing novel drugs in two therapeutic areas: cancer and autoimmune diseases. MediGene is the first German biotech
company that has drugs on the market. Until now, our drugs are distributed by partner companies. MediGene has several drug candidates in clinical development, some of which
providing substantial sales potential. In addition, we possess innovative platform technologies which enable the search for other therapeutic substances. Licensed products
complement our proprietary drug portfolio. This allows us to reduce risks, enhance our opportunities, and accellerate revenue generation.
Further Information
For further information please see our press releases, have a look at our annual and quarterly reports, or contact us by phone or
e-mail.
MediGene at a glance
- founded in 1994 as a Munich Gene Center spin-off
- June 2000: IPO, listed on the Frankfurt Stock Exchange
- January 2001: acquisition of the US biotechnology company NeuroVir
- 2004: Acquisition of products and technology of Munich Biotech AG
- 2006: Acquisition of the British biotechnology company Avidex Limited
- about 110 employees
- focus on cancer
- two drugs on the market
- further drug candidates undergoing clinical trials
- novel technology platforms
|
 |
|
|
|
|
MediGene, Inc.
San Diego, CA
How to find MediGene, Inc. |
MediGene, Ltd.
Milton Park, Oxford, GB
|
|
|
|
